Financial Lp Hrt Sells 34,938 Shares of Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) major shareholder Financial Lp Hrt sold 34,938 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $1.40, for a total transaction of $48,913.20. Following the sale, the insider directly owned 92,055 shares of the company’s stock, valued at approximately $128,877. This represents a 27.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, July 9th, Financial Lp Hrt purchased 64,047 shares of Bluejay Diagnostics stock. The stock was acquired at an average price of $1.51 per share, for a total transaction of $96,710.97.

Bluejay Diagnostics Trading Up 2.5%

BJDX opened at $1.25 on Wednesday. The firm’s 50 day simple moving average is $2.67 and its two-hundred day simple moving average is $2.47. The company has a market capitalization of $1.29 million, a PE ratio of -0.11 and a beta of 0.88. Bluejay Diagnostics, Inc. has a 1-year low of $1.03 and a 1-year high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. Institutional investors and hedge funds own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.